Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 December 2024

Swixx BioPharma
CHF
192
million
CHF
172
million
Shanghai Cathay Biotech
CHF
67
million
Harmony Biosciences
Neurelis
CHF
51
million
CHF
45
million
Fangzhou (Jianke)
Upstream Bio
CHF
41
million
ArriVent Biopharma
CHF
36
million